Great Lakes NeuroTechnologies Allowed Patent Claims Covering Therapy and Diagnostic Device Combinations

VIEW PDF

17 MAR 2020: Independence, OH – Great Lakes NeuroTechnologies The United States Patent Office issued a notice of allowance and awarded Great Lakes NeuroTechnologies (GLNT) patent claims in application 16/108,746 covering a therapy and diagnostic device combination for providing and adjusting therapy for a movement disorder treatment. This unique technology will utilize real-world evidence of movement disorder symptoms and apply artificial intelligence to adjust advanced therapies such as deep brain stimulation (DBS) and drug pumps.

GLNT commercialized Kinesia™ technology [ http://www.glneurotech.com/kinesia ] to provide wearable, objective and automated assessment of movement disorder such as Parkinson’s disease (PD) and essential tremor (ET). The clinically validated technology has been adopted as the gold-standard for objective sensor measurement for movement disorders by many of the world’s leading pharmaceutical and medical device companies. Last year, GLNT released the KinesiaU™ motor assessment system [ http://www.KinesiaU.com ], a prescription app that allows individuals to measure their Parkinson’s disease symptoms using consumer smartwatches and share their data with their doctors. KinesiaU also can assist in telemedicine visits, allowing Parkinson’s patients to avoid travel in a COVID-19 environment.

According Great Lakes NeuroTechnologies President and COO, Dustin Heldman, Ph.D., “We are very excited about these newly allowed claims as we progress from measuring symptoms to developing platforms for precision medicine and a personalized approach to PD management. The Kinesia technology provides reliable real-world evidence that, when combined with a drug or other device and pharmacokinetic modes, may allow for algorithms to predict optimal therapy regimens, provide on-demand dosing, and change therapy delivery in real-time.”

Dr. Heldman thanks the NIH for their continued support through the SBIR program, specifically the National Institute of Neurological Disorders and Stroke and the National Center on Minority Health and Health Disparities (2R44NS043816-04 and 1R43MD004049-01). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies [ http://www.glneurotech.com ] is committed to pioneering innovative biomedical technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world. Kinesia and KinesiaU are trademarks of Great Lakes NeuroTechnologies Inc. of Independence, OH.

Media Contacts

Margaret Bartholomew 216-361-5410 mbartholomew@GLNeuroTech.com